Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadaaki Yamada

Showing results (51-60 of 228) with videos related to

Pageof 23
Sort By:
Molecular Cancer Therapeutics|February 1, 2017
<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung CancerShigeki Nanjo, Sachiko Arai, Wei Wang, et al.
The Oncologist|March 13, 2020
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung CancerKoichi Takayama, Masao Ichiki, Takemasa Matsumoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2012
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective]Tadaaki Yamada, Koushiro Ohtsubo, Daisuke Ishikawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung CancerTakehito Shukuya, Tadaaki Yamada, Michael J Koenig, et al.
Therapeutic Advances in Medical Oncology|June 19, 2023
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in <i>EGFR</i> exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura, et al.
Thoracic Cancer|January 23, 2019
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancerYuki Katayama, Tadaaki Yamada, Keiko Tanimura, et al.
Cancer Science|May 6, 2017
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathwayHirokazu Taniguchi, Tadaaki Yamada, Shinji Takeuchi, et al.
Japanese Journal of Clinical Oncology|July 6, 2010
The role of percutaneous needle biopsy in differentiation of renal tumorsKouji Izumi, Kazutaka Narimoto, Kazuhiro Sugimoto, et al.
Molecular Cancer Therapeutics|January 14, 2009
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient miceTadaaki Yamada, Hiroaki Muguruma, Seiji Yano, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Antiangiogenic therapies for malignant pleural mesotheliomaSeiji Yano, Qi Li, Wei Wang, et al.
Pageof 23

Showing results (51-60 of 228) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|February 1, 2017
<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung CancerShigeki Nanjo, Sachiko Arai, Wei Wang, et al.
The Oncologist|March 13, 2020
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung CancerKoichi Takayama, Masao Ichiki, Takemasa Matsumoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2012
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective]Tadaaki Yamada, Koushiro Ohtsubo, Daisuke Ishikawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung CancerTakehito Shukuya, Tadaaki Yamada, Michael J Koenig, et al.
Therapeutic Advances in Medical Oncology|June 19, 2023
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in <i>EGFR</i> exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura, et al.
Thoracic Cancer|January 23, 2019
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancerYuki Katayama, Tadaaki Yamada, Keiko Tanimura, et al.
Cancer Science|May 6, 2017
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathwayHirokazu Taniguchi, Tadaaki Yamada, Shinji Takeuchi, et al.
Japanese Journal of Clinical Oncology|July 6, 2010
The role of percutaneous needle biopsy in differentiation of renal tumorsKouji Izumi, Kazutaka Narimoto, Kazuhiro Sugimoto, et al.
Molecular Cancer Therapeutics|January 14, 2009
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient miceTadaaki Yamada, Hiroaki Muguruma, Seiji Yano, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Antiangiogenic therapies for malignant pleural mesotheliomaSeiji Yano, Qi Li, Wei Wang, et al.
Pageof 23